Leustatin Related Published Studies
Well-designed clinical trials related to Leustatin (Cladribine)
Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis: Analysis of Economic Data from the CLARITY Study. [2012.01.01]
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. [2011.05]
Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). [2010.04.10]
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. [2010.02.04]
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). [2010.02]
Development of oral cladribine for the treatment of multiple sclerosis. [2010]
Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. [2009.08]
Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. [2009.06]
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). [2006.07.15]
Cladribine for multiple sclerosis: review and current status. [2005.11]
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). [2005.10]
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. [2004.05]
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. [2003.12]
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. [2002.10.15]
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. [2001.10]
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. [2001.01]
Whole brain volume changes in patients with progressive MS treated with cladribine. [2000.12.12]
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. [2000.10.15]
The effect of cladribine on T(1) 'black hole' changes in progressive MS. [2000.05.01]
Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. [2000.03.14]
The cladribine trial in secondary progressive multiple sclerosis: A reanalysis. [2000.03]
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. [2000.02]
Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients. [2000.02]
A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. [1999.01]
[Chronic lymphatic leukemia. Peroral cladribine as primary treatment] [1996.11.04]
Development of cladribine treatment in multiple sclerosis. [1996.07]
The treatment of chronic progressive multiple sclerosis with cladribine. [1996.02.20]
Cladribine in treatment of chronic progressive multiple sclerosis. [1994.07.02]
Well-designed clinical trials possibly related to Leustatin (Cladribine)
Pathogenesis and Treatment of Anti-MAG Neuropathy. [2010.03]
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. [2006.08]
Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS. [2005.11]
New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients. [2000]
Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial. [1999.11]
Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. [1999.07]
2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. [1998.01]
A comparison of two neurologic scoring instruments for multiple sclerosis. [1996.03]
The value of magnetic resonance imaging in diagnosis and monitoring of treatment in multiple sclerosis. [1996]
The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. [1994]
Treatment of hairy-cell leukemia. [1990.12]
Other research related to Leustatin (Cladribine)
Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. [2011.06.16]
Hairy cell leukemia: epidemiology, pharmacokinetics of cladribine, and long-term follow-up of subcutaneous therapy. [2011.06]
Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. [2011.06]
Development of cladribine at Scripps for hairy cell leukemia and current results. [2011.06]
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence. [2011.06]
Alternative methods of cladribine administration. [2011.06]
Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping. [2011.06]
Mechanism of action of pentostatin and cladribine in hairy cell leukemia. [2011.06]
Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy. [2011.06]
Response to cladribine in patient with systemic mastocytosis. [2011.05]
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. [2011.04]
Cladribine tablets: in relapsing-remitting multiple sclerosis. [2011.03.01]
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma. [2011.02]
Evaluation of Cladribine treatment in refractory celiac disease type II. [2011.01.28]
Cladribine: mode of action and implications for treatment of multiple sclerosis. [2011.01]
Beyond hairy cell: the activity of cladribine in other hematologic malignancies. [2010.10.21]
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis. [2010.10.05]
In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. [2010.09]
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. [2010.07.21]
[Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs] [2010.04]
Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). [2010.04]
Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. [2010.03.11]
Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis. [2010.03]
Development of oral cladribine for the treatment of multiple sclerosis. [2010.02]
R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis. [2010.01.01]
Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. [2010.01.01]
The cladribine conundrum: deciphering the drug's mechanism of action. [2010.01]
Infectious complications in patients with acute myeloid leukemia treated
according to the protocol with daunorubicin and cytarabine with or without
addition of cladribine. A multicenter study by the Polish Adult Leukemia Group
(PALG). [2010]
Cladribine inhibits a diltiazem-induced increase in red blood cell purine nucleotide concentrations in a zebrafish model. [2009.12]
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. [2009.11.19]
Cladribine treatment in two-hour intravenous infusion for previously-treated low grade B-cell lymphoma: a pilot study. [2009.11]
Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. [2009.10]
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single agent cladribine and with more aggressive behavior. [2009.08.10]
Cladribine in the treatment of acute myeloid leukemia: a single-institution experience. [2009.08]
Cladribine: not just another purine analogue? [2009.08]
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). [2009.07.04]
Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. [2009.07]
[Hairy cell leukemia: Part II: therapy with cladribine] [2009.07]
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. [2009.06]
Clinical evaluation of busulfan, cladribine and alemtuzumab as reduced intensity conditioning for stem cell transplantation. [2009.04]
Successful treatment of central nervous system juvenile xanthogranulomatosis with cladribine. [2009.03]
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. [2009.03]
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. [2009.01.16]
Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion: report from the Polish Adult Leukemia Group. [2009.01.01]
Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom. [2009]
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. [2008.12]
Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis. [2008.11]
Cladribine tablets' potential in multiple: sclerosis treatment. [2008.10]
Characterisation of an inclusion complex between cladribine and 2-hydroxypropyl-beta-cyclodextrin. [2008.09]
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. [2008.07.15]
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. [2008.07.01]
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. [2008.05.09]
Cladribine in indolent non-Hodgkin's lymphoma. [2008.04]
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. [2008.02]
Combined treatment with splenectomy and cladribine in hairy cell leukemia in Taiwan: a clinicopathologic study of 5 cases. [2007.12]
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. [2007.11.15]
[Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia] [2007.11]
The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. [2007.11]
[Combination therapy with rituximab and cladribine for patients with follicular lymphoma] [2007.10]
Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. [2007.08]
Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. [2007.08]
Cladribine in aggressive forms of multiple sclerosis. [2007.06]
|
